TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Bioxyne Limited ( (AU:BXN) ) is now available.
Bioxyne Limited announced significant growth and strategic advancements at its 2025 Annual General Meeting. The company reported record sales and profits for FY2025, driven by its expansion in manufacturing capacity and international markets, particularly in Europe. Bioxyne’s release of Australian-made GMP MDMA capsules for clinical trials marks a milestone in mental health treatment, positioning the company at the forefront of the psychedelic therapeutics market. The company also secured major contracts and invested in infrastructure to support its growth, achieving a 210% increase in quarterly revenue in Q1 FY2026.
More about Bioxyne Limited
Bioxyne Limited is a pharmaceutical and consumer health company listed on the ASX, known for its manufacturing and distribution of controlled medicines and innovative healthcare solutions. Through its subsidiary, Breathe Life Sciences, it is Australia’s first TGA GMP-licensed manufacturer of psychedelic and psychoactive medicines, including cannabis, psilocybin, and MDMA. The company focuses on white-label contract manufacturing and has a significant presence in the Australian, UK, and European markets.
Average Trading Volume: 3,664,650
Technical Sentiment Signal: Buy
Current Market Cap: A$81.02M
Learn more about BXN stock on TipRanks’ Stock Analysis page.